Having trouble accessing articles? Reset your cache.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/28 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy -2% $82.34
Aschoff raised his target to $93 from $83 after updating his model and taking into account projected revenues out to 2014 for Soliris eculizumab and adding revenue for anti-kidney transplant rejection. The humanized mAb, which targets complement 5 (C5), is approved in Canada, EU, U.S. and Japan to

Read the full 880 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE